IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,419 shares of the company’s stock after selling 31,755 shares during the quarter. IDEXX Laboratories comprises approximately 1.3% of TimesSquare Capital Management LLC’s investment portfolio, making the stock its 19th largest holding. TimesSquare Capital Management LLC owned 0.19% of IDEXX Laboratories worth $87,930,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. International Assets Investment Management LLC boosted its holdings in IDEXX Laboratories by 51,631.3% during the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after buying an additional 546,775 shares in the last quarter. Winslow Capital Management LLC raised its holdings in IDEXX Laboratories by 24.9% in the 3rd quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock worth $301,661,000 after purchasing an additional 137,621 shares during the period. Barclays PLC grew its holdings in IDEXX Laboratories by 46.7% in the third quarter. Barclays PLC now owns 248,476 shares of the company’s stock valued at $108,651,000 after purchasing an additional 79,102 shares during the period. abrdn plc increased its position in shares of IDEXX Laboratories by 46.5% in the fourth quarter. abrdn plc now owns 246,130 shares of the company’s stock valued at $136,614,000 after buying an additional 78,166 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of IDEXX Laboratories by 51.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 225,150 shares of the company’s stock valued at $98,353,000 after buying an additional 76,350 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 2.8 %

Shares of NASDAQ IDXX traded up $13.75 during mid-day trading on Thursday, hitting $500.82. The company had a trading volume of 546,581 shares, compared to its average volume of 445,009. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company has a market capitalization of $41.36 billion, a PE ratio of 48.48, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The business’s 50-day simple moving average is $517.91 and its 200 day simple moving average is $514.15.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same quarter last year, the company earned $2.05 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. The Goldman Sachs Group increased their target price on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. boosted their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. Finally, Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $580.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.